Tests divarasib with pembrolizumab against standard chemotherapy in untreated lung cancer
Tests divarasib and pembrolizumab in adults with KRAS G12C-mutated advanced non-squamous lung cancer.
Key facts
- Who runs it
- F. Hoffmann-La Roche AG
- Where
- Århus, Copenhagen Oe, Herlev, Herning, Roskilde, and Soenderborg, DenmarkSee the 6 sitesAlso in 11 other countries, 117 sites
- Trial code
- Registry title
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 282 people, planned
- Started
- 9 Nov 2026
- Expected to end
- 30 Dec 2030
- Type of study
- Interventional
- Record updated
- 6 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic non-squamous non-small cell lung cancer who have a KRAS G12C mutation and have had no earlier drug treatment for this cancer.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced or metastatic non-squamous non-small cell lung cancer that cannot be treated with surgery or full-dose chemotherapy with radiation meant to remove all of the disease. Measurable disease by RECIST v1.1.
- Earlier treatment
- No earlier systemic (whole-body) treatment for advanced or metastatic lung cancer.
- Biomarker or test result
- A KRAS G12C mutation shown by lab testing of a tumor sample, or by an earlier test result on blood or tumor tissue.
Main reasons for not taking part
- Brain or spinal cord metastases that cause symptoms, are untreated or are actively growing
- Another known cancer-driving gene change that has an available targeted treatment
- Earlier treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors
- Major surgery within 4 weeks before randomization, or a major surgery expected during the study
- Significant heart or blood vessel disease within 3 months before screening
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, with assessment scale
- Life expectancy of at least 12 weeks
- Measurable disease, as defined by RECIST v1.1
- No prior systemic treatment for advanced or metastatic non−small cell lung cancer (NSCLC)
- Documentation of the presence of a KRAS G12C mutation either through central laboratory testing of a tumor tissue sample (as per local IVD regulations), or preexisting test results of a blood or tumor tissue sample
- Histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy
Who cannot take part
- Known concomitant second oncogenic driver with available targeted treatment
- Prior treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors
- Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the study
- Palliative radiation to bone metastases within 2 weeks prior to randomization to ensure adequate recovery from the effects of radiotherapy
- Significant cardiovascular disease within 3 months prior to screening
- Symptomatic, untreated, or actively progressing CNS metastases
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which best describes your lung cancer?
- Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?
- Has your cancer spread to the brain?
Where in Denmark
Also in 11 other countries, 117 sites
- Aarhus UniversitetshospitalÅrhus, DenmarkTaking people
- RigshospitaletCopenhagen Oe, DenmarkTaking people
- Herlev og Gentofte HospitalHerlev, DenmarkTaking people
- Regionshospitalet GoedstrupHerning, DenmarkTaking people
- Zealand University HospitalRoskilde, DenmarkTaking people
- Region SyddanmarkSoenderborg, DenmarkTaking people
About the trial
What the trial wants to find out
To evaluate the efficacy of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin with respect to progression-free survival (PFS) and overall survival (OS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
- Plain-language title
- Tests divarasib with pembrolizumab against standard chemotherapy in untreated lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 10 November 2026.
- Fit questions
- Built from 2024-518365-10-00, who can take part
- Record updated
- 6 October 2026